Breaking News
Home / Business News (page 10)

Business News

Calixar Signs Exclusive Licensing Agreement with Regeneron for Rights to its Technology for Antibody Discovery

Lyon, France, April 29, 2019 – Calixar SAS (Calixar), a biotechnology company specialized in native membrane protein stabilization, announces today that it has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Calixar has given Regeneron exclusive rights to its technology and expertise …

Read More »

Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric Bispecific Platform

VANCOUVER, British Columbia VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) announced today that Daiichi Sankyo has exercised its option for a commercial license to a proprietary immuno-oncology bispecific built on …

Read More »

Salix and Mitsubishi Tanabe Pharma Enter Exclusive Agreement to Develop and Commercialize Investigational Treatment for Inflammatory Bowel Disease

BRIDGEWATER, N.J., April 25, 2019 /PRNewswire/ — Salix Pharmaceuticals (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, and a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), announced today that its affiliate has entered …

Read More »

Macrogen and Exosome Plus to Jointly Develop Exosome-based Diagnostic and Treatment Solutions

SEOUL, South Korea–(BUSINESS WIRE)–The precision medicine and biotechnology company Macrogen (CEO Kap-Seok Yang, www.macrogen.com/en/) announced on April 24 that it had signed a supply contract with Exosome Plus (CEO Jong-Uk Bu, www.exosomeplus.com) on April 19 to become the exclusive buyer of the exosome isolation kits developed by Exosome Plus. The two companies also signed an MOU …

Read More »

UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

NEW YORK–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest. …

Read More »

Fulcrum Acquires Global Rights to Losmapimod, a Potential Therapy for Facioscapulohumeral Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Fulcrum Therapeutics, a biotechnology company focused on discovering and developing therapies to rebalance gene expression, today announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum intends to advance losmapimod into a Phase 2b trial in the rare and …

Read More »

FSD Pharma to Acquire Prismic Pharmaceuticals for $17.5 Million

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD Pharma has agreed …

Read More »

Lilly and Avidity Biosciences Enter License and Research Collaboration in Immunology and Other Indications

INDIANAPOLIS and LA JOLLA, Calif., April 22, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications. The companies will utilize Avidity’s technology platform to progress new therapeutic approaches toward …

Read More »

OncoSec and Duke University School of Medicine Collaborate in HER2+ Breast Cancer Evaluating TAVO with Plasmid DNA Vaccines

SAN DIEGO and PENNINGTON, N.J., April 17, 2019 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, today announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary TAVOPLUS (enhanced IL-12 DNA-plasmid) …

Read More »

Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Retinal Diseases and Changes Name to IVERIC bio

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the Company is changing its name to IVERIC bio, Inc. In conjunction with the corporate name …

Read More »